Pharmacokinetics, pharmacodynamics, safety and tolerability of 4 weeks' treatment with empagliflozin in Japanese patients with type 2 diabetes mellitus

Journal of Diabetes Investigation

Volumn 4, Issue 6, 2013, Pages 613-617

  Kanada, Shigeto ^a   Koiwai, Kazuki ^b   Taniguchi, Atsushi ^b   Sarashina, Akiko ^b   Seman, Leo ^c   Woerle, Hans J ^d  

^a Osaka Clinical Research Organization for Medicine Clinic   (Japan)

^b NIPPON BOEHRINGER INGELHEIM CO LTD   (Japan)

^c BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Diabetes; Empagliflozin; Sodium glucose cotransporter 2 inhibitor

Indexed keywords

EMPAGLIFLOZIN; GLUCOSE; PLACEBO;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CONSTIPATION; CONTROLLED STUDY; CYSTITIS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; JAPANESE; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NOCTURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PARALLEL DESIGN; PHARMACODYNAMICS; POLLAKISURIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; TREATMENT DURATION; UPPER ABDOMINAL PAIN;

EID: 84888435301     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/jdi.12110     Document Type: Article

References (14)

1. Whiting DR, Guariguata L, Weil C, et al. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011; 94: 311-321.
2. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010; 87: 4-14.
3. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053.
4. Neville SE, Boye KS, Montgomery WS, et al. Diabetes in Japan: a review of disease burden and approaches to treatment. Diabetes Metab Res Rev 2009; 25: 705-716.
5. Esposito K, Chiodini P, Bellastella G, et al. Proportion of patients at HbA1c target <7% with 8 classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78 945 patients. Diabetes Obes Metab 2012; 14: 228-233.
6. Cefalu WT. Evolving treatment strategies for the management of type 2 diabetes. Am J Med Sci 2012; 343: 21-26.
7. DeFronzo RA. Overview of newer agents: where treatment is going. Am J Med 2010; 123: S38-S48.
8. Cobble ME, Peters AL. Clinical practice in type 2 diabetes: after metformin and lifestyle, then what? J Fam Pract 2009; 58: S7-S14.
9. Pollack MF, Purayidathil FW, Bolge SC, et al. Patient-reported tolerability issues with oral antidiabetic agents: associations with adherence; treatment satisfaction and health-related quality of life. Diabetes Res Clin Pract 2010; 87: 204-210.
10. Bakris GL, Fonseca VA, Sharma K, et al. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int 2009; 75: 1272-1277.
11. Grempler R, Thomas L, Eckhardt M, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 2012; 14: 83-90.
12. Heise T, Seewaldt-Becker E, Macha S, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes Obes Metab 2013; 15: 613-621doi: 10.1111/dom.12073 [Epub ahead of print].
13. Seman L, Macha S, Nehmiz G, et al. Empagliflozin (BI 10773), a potent and selective SGLT-2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clinical Pharm in Drug Dev 2013; 2: 152-161doi 10.1002/cpdd.16 [Epub ahead of print].
14. Sarashina A, Koiwai K, Seman LJ, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, in healthy Japanese subjects. Drug Metab Pharmacokinet 2012.????: ???-???? [Epub ahead of print].